CJC-1295 vs Sermorelin

Overview

CJC-1295 and sermorelin are both growth hormone releasing hormone (GHRH) analogs that stimulate pituitary GH release. CJC-1295 is a modified peptide designed for extended half-life, while sermorelin has a structure closer to natural GHRH with a short half-life.

Important: Sermorelin was previously FDA-approved (discontinued); CJC-1295 has never been approved. Both are now available through compounding pharmacies or as research chemicals.

Key Facts

Aspect	CJC-1295	Sermorelin
Class	Modified GHRH analog	GHRH analog (natural sequence)
Structure	GHRH 1-29 with modifications	GHRH 1-29
FDA Status	Never approved	Previously approved (Geref, discontinued)
Half-life	~6-8 days (with DAC) or ~30 min (no DAC)	~10-20 minutes
Availability	Research chemical / compounding	Compounding pharmacies

Types of CJC-1295

Important distinction: CJC-1295 exists in two forms with very different properties:

Type	Half-life	Dosing	Also Known As
CJC-1295 with DAC	~6-8 days	Weekly or less	Drug Affinity Complex
CJC-1295 without DAC	~30 minutes	Multiple daily	Modified GRF 1-29, Mod GRF

The DAC (Drug Affinity Complex) allows CJC-1295 to bind to albumin, dramatically extending its half-life.

Mechanism Comparison

Aspect	CJC-1295	Sermorelin
Target	GHRH receptor	GHRH receptor
Mechanism	GHRH mimetic	GHRH mimetic
GH Release Pattern	Sustained (with DAC) or pulsatile (no DAC)	Pulsatile
Physiologic Pattern	Less natural (with DAC)	More natural
Feedback Intact	Yes	Yes

How They Work

CJC-1295:

• Modified version of GHRH 1-29
• Amino acid substitutions prevent degradation by DPP-IV
• DAC version binds albumin for extended half-life
• Non-DAC version has similar kinetics to sermorelin
• Stimulates GH synthesis and release via GHRH-R

Sermorelin:

• First 29 amino acids of natural 44-amino acid GHRH
• Retains full biological activity
• Rapidly degraded by enzymes
• Short half-life mimics natural GHRH pulsatility
• Works through physiologic GHRH pathway

Half-Life Implications

Aspect	CJC-1295 with DAC	CJC-1295 no DAC	Sermorelin
Half-life	6-8 days	~30 minutes	10-20 minutes
GH pattern	Sustained elevation	Pulsatile	Pulsatile
Natural rhythm	Disrupted	Preserved	Preserved
Convenience	Higher	Lower	Lower

Pulsatile vs Sustained GH

Natural GH secretion: Occurs in pulses, primarily during sleep, with periods of low GH between pulses.

CJC-1295 with DAC: Creates sustained GH elevation, which may:

• Be more convenient (less frequent dosing)
• Potentially disrupt normal feedback mechanisms
• Have different metabolic effects than pulsatile release

Sermorelin/CJC-1295 no DAC: Better mimics natural pulsatile pattern but requires more frequent dosing.

Evidence Quality

CJC-1295 Research

Trial Type	Status	Key Findings
Phase 1/2 studies	Some completed	GH/IGF-1 elevation demonstrated
Long-term efficacy	Not established	—
Safety data	Limited	Some adverse events in trials
FDA development	Not pursued	—

Research limitations:

• Development halted after adverse events in early trials
• Limited published peer-reviewed data
• Most use is based on mechanistic rationale
• No Phase 3 trials completed

Sermorelin Research

Trial Type	Status	Key Findings
Pediatric GH testing	FDA approved (1997)	Diagnostic use
Adult studies	Limited	Variable results
Long-term safety	Limited	No major concerns identified
Post-marketing	Available until 2008	Commercial discontinuation

Historical context:

• FDA approval provided some safety validation
• Discontinued for commercial reasons, not safety
• Limited data for anti-aging indications

Evidence Strength Comparison

Factor	CJC-1295	Sermorelin
FDA review	None	Previously approved
Published RCTs	Very few	Some
Long-term safety	Unknown	Limited but cleaner
Development status	Halted	Discontinued (commercial)
Overall quality	Low	Low-Moderate

Side Effects

CJC-1295 (Limited Data)

Side Effect	Reported	Notes
Injection site reactions	Common	Redness, irritation
Flushing	Reported	Transient
Headache	Reported	—
Water retention	Possible	GH-related
Dizziness	Reported	—

Notable concern: Early CJC-1295 trials reported cardiac events that contributed to halted development. Causality was not definitively established.

Sermorelin (Limited Data)

Side Effect	Reported	Notes
Injection site reactions	Common	Pain, swelling
Facial flushing	Occasional	Transient
Headache	Occasional	Usually mild
Dizziness	Rare	—

Safety Considerations

CJC-1295 with DAC concerns:

• Sustained GH elevation may have different effects than pulsatile
• Less physiologic GH pattern
• Limited safety data
• Historical development concerns

Sermorelin advantages:

• More physiologic GH pattern
• Cleaner historical safety record
• Previously FDA-approved (some validation)

Practical Comparison

Factor	CJC-1295 with DAC	CJC-1295 no DAC	Sermorelin
Injection frequency	1-2x weekly	2-3x daily	1-2x daily
Convenience	Higher	Lower	Lower
GH pattern	Sustained	Pulsatile	Pulsatile
Physiologic	Less	More	More
Combination use	Often standalone	Often with GHRP	Often with GHRP

Availability Comparison

Factor	CJC-1295	Sermorelin
Legal status	Research chemical	Compounded medication
Prescription available	Sometimes (compounding)	Yes
Quality assurance	Variable	Compounding standards
Medical oversight	Often lacking	Available
Cost	Variable	Variable

Combination Protocols

Both compounds are often combined with GHRPs for enhanced effect:

Common Combinations

Combination	Rationale
CJC-1295 no DAC + Ipamorelin	GHRH + GHRP synergy, popular “stack”
CJC-1295 no DAC + GHRP-6	GHRH + GHRP, stronger hunger effect
Sermorelin + Ipamorelin	GHRH + GHRP, cleaner profile
CJC-1295 with DAC + Ipamorelin	Convenience + selectivity

Evidence for combinations: Largely theoretical based on receptor pharmacology; clinical validation lacking.

Clinical Context

Anti-Aging Clinics

Both peptides are commonly prescribed by anti-aging and longevity clinics:

• Usually combined with GHRPs
• Monitoring IGF-1 levels standard practice
• Variable protocols and dosing
• Limited standardization

Compounding Pharmacy Access

Aspect	Considerations
Prescription required	Yes (for legitimate compounding)
Quality standards	USP/state regulations
Testing	Varies by pharmacy
Physician oversight	Required

Who Might Consider Each

CJC-1295 with DAC:

• Those prioritizing convenience (less frequent dosing)
• Those accepting non-physiologic GH pattern
• Concern: Limited safety data, sustained elevation effects unknown

CJC-1295 without DAC:

• Those wanting enhanced GHRH effect
• Often combined with GHRPs
• Preserves pulsatile GH release
• Similar to sermorelin but modified

Sermorelin:

• Those wanting closer-to-natural peptide
• Previous FDA approval provides some reassurance
• Cleaner safety history
• Available through legitimate compounding channels

Summary

Factor	CJC-1295 with DAC	CJC-1295 no DAC	Sermorelin
Half-life	Days	Minutes	Minutes
GH pattern	Sustained	Pulsatile	Pulsatile
Evidence quality	Low	Low	Low-Moderate
FDA history	Never approved	Never approved	Previously approved
Convenience	High	Low	Low
Physiologic	Less	More	More

Key takeaway: CJC-1295 with DAC offers dosing convenience at the cost of physiologic GH patterns and limited safety data. CJC-1295 without DAC and sermorelin both provide pulsatile GH release; sermorelin has a cleaner regulatory history. None are FDA-approved for anti-aging or body composition uses.

---

This comparison is for educational purposes only. CJC-1295 has never been FDA-approved. Sermorelin is available through compounding pharmacies. Consult a healthcare provider before considering any GH secretagogue.